IDEAYA Biosciences IDYA 深 滬
已收盤 02-06 16:00:00 美东时间
32.17
+0.400
+1.26%
華盛通- 最 高33.00
- 今 開32.68
- 成交量 98.53万股
- 最 低 31.855
- 昨 收 31.77
- 總市值 28.20亿
- 52周最高 39.28
- 市盈率 靜 --
- 換手率 1.12%
- 52周最低 13.45
- 委 比 -23.15%
- 總股本 8766.64万
- 歷史最高 47.735
- 量 比 1.30
- 振 幅 3.60%
- 歷史最低 2.95
- 每 手 1
- 風險率 6.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多IDEAYA Biosciences Grants Stock Options to New Employee Under Inducement Plan
IDEAYA Biosciences Grants Stock Options to New Employee Under Inducement Plan IDEAYA Biosciences Inc. has granted non-qualified stock options to a newly hired employee, allowing the purchase of 44,200 shares of company common stock at an exercise price of $32.99 per share, matching the closing price
01-30 19:00
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of target...
01-30 19:00
美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $45
RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $41 to $45.
01-21 22:48
IDEAYA updates precision oncology strategy at JPM 2026
IDEAYA Biosciences ( ($IDYA) ) has provided an update. On January 12, 2026, IDE...
01-12 19:30
IDEAYA sets 2026 objectives to advance registrational trials
IDEAYA Biosciences ( ($IDYA) ) has provided an announcement. On January 11, 202...
01-12 19:29
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Truist Securities Maintains Buy on IDEAYA Biosciences, Raises Price Target to $60
Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $59 to $60.
01-06 23:13
IDEAYA CEO to Outline Cancer Drug Pipeline at Major JPMorgan Conference
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 44th Annual J.P. Morgan Healthcare
01-05 19:06
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targete...
01-05 19:00
